Accessible, high-quality medicine you can trust—delivered with excellence and care since 1966.
Certified by leading global regulatory authorities—including the U.S. FDA, EU EMA, Japan PMDA, Taiwan TFDA, China NMPA, and Brazil ANVISA—our manufacturing sites meet the highest global standards for safety, efficacy, and quality of our products.
We uphold rigorous quality management across every stage of production and cultivate a company‑wide culture where quality is foundational. This commitment ensures our products consistently earn the trust of patients, healthcare providers, and global partners.
Business
Feb 24, 2026
Taipei, Taiwan, 24 February 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has filed a New Drug Application (“NDA”) under the 505(b)(2) regulator...
Business
Feb 23, 2026
Solaxa and Alvogen enter into license agreement for the development and commercialization of SLX-100 for spinocerebellar ataxia type 27B (SCA27B) Alvogen will acquire worldwide rights for SLX-100 for SCA27B and will be responsible for the co...
Business
Feb 11, 2026
Planegg-Martinsried, Germany and Taipei, Taiwan, 11 February 2026 – Formycon AG (FWS: FYB, “Formycon”) and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon&rsqu...
